Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Granulocyte colony stimulating factor biobetter - UBI Pharma

Next Previous
X
Search
Drug Profile

Granulocyte colony stimulating factor biobetter - UBI Pharma

Alternative Names: Long acting GCSF - UBI Pharma; UB 853

Latest Information Update: 25 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UBI Pharma
  • Class Antineoplastics; Biobetters; Chemoprotectants; Granulocyte colony-stimulating factors; Recombinant fusion proteins
  • Mechanism of Action Granulocyte colony stimulating factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Neutropenia

Most Recent Events

  • 25 Sep 2024 Preclinical trials in Neutropenia in Taiwan (Parenteral), prior to September 2024 (UBI Pharma pipeline, September 2024)
  • 20 Dec 2023 Early research in Neutropenia in Taiwan (Parenteral) (UBI Pharma pipeline, December 2023)
  • 21 Nov 2023 UBI Pharma has patent protection for immunoglobulin fusion proteins in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top